ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
-0,66%
Bitcoin
60 191,52
-2,30%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
27/06/202422h15Business WireSummit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
18/06/202423h14Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SMMTSummit Therapeutics Inc
17/06/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/06/202420h03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SMMTSummit Therapeutics Inc
03/06/202411h30Business WireSummit Raises $200 Million; Also Expands License Territories for IvonescimabNASDAQ:SMMTSummit Therapeutics Inc
01/06/202414h00Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
01/06/202401h00Business Wire Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyNASDAQ:SMMTSummit Therapeutics Inc
31/05/202400h00Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
30/05/202420h29Business WireIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaNASDAQ:SMMTSummit Therapeutics Inc
13/05/202413h48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SMMTSummit Therapeutics Inc
01/05/202413h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024NASDAQ:SMMTSummit Therapeutics Inc
24/04/202422h30Business WireSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024NASDAQ:SMMTSummit Therapeutics Inc
11/04/202422h30Business WireSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
10/04/202413h00Business WireSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumNASDAQ:SMMTSummit Therapeutics Inc
22/03/202412h00Business WirePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
14/03/202412h00Business WireIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
05/03/202413h00Business WireSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h55Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
14/02/202422h35Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
14/02/202416h29Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024NASDAQ:SMMTSummit Therapeutics Inc
14/02/202413h00Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023NASDAQ:SMMTSummit Therapeutics Inc
07/02/202413h00Business WireSummit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
08/01/202415h00Business WireSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
04/01/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
03/01/202413h30Business WireSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
07/11/202314h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
07/11/202313h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023NASDAQ:SMMTSummit Therapeutics Inc
02/11/202321h41Business WireLaura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

LSE
BK18
Cred Ag Co 27
TG
A1ZVJQ
Enagas Financiaciones SAU
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés